MDT

83.73

+1.05%↑

VEEV

215.31

+0.77%↑

A

104.38

+3.85%↑

HQY

80.66

+5.44%↑

PDCO

31.08

+0.45%↑

MDT

83.73

+1.05%↑

VEEV

215.31

+0.77%↑

A

104.38

+3.85%↑

HQY

80.66

+5.44%↑

PDCO

31.08

+0.45%↑

MDT

83.73

+1.05%↑

VEEV

215.31

+0.77%↑

A

104.38

+3.85%↑

HQY

80.66

+5.44%↑

PDCO

31.08

+0.45%↑

MDT

83.73

+1.05%↑

VEEV

215.31

+0.77%↑

A

104.38

+3.85%↑

HQY

80.66

+5.44%↑

PDCO

31.08

+0.45%↑

MDT

83.73

+1.05%↑

VEEV

215.31

+0.77%↑

A

104.38

+3.85%↑

HQY

80.66

+5.44%↑

PDCO

31.08

+0.45%↑

Search

AstraZeneca PLC ADR

Отворен

64.56 -5.68

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

63.58

Максимум

68.45

Ключови измерители

By Trading Economics

Приходи

-162M

1.7B

Продажби

1.3B

15B

P/E

Средно за сектора

32.667

63.778

EPS

1.045

Дивидентна доходност

2.11

Марж на печалбата

11.188

Служители

94,300

EBITDA

330M

4.4B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+36.11% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.11%

2.39%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

228B

Предишно отваряне

70.24

Предишно затваряне

64.56

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

AstraZeneca PLC ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.03.2025 г., 03:15 ч. UTC

Значими двигатели на пазара

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17.03.2025 г., 07:42 ч. UTC

Придобивния, сливания и поглъщания

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

3.04.2025 г., 08:41 ч. UTC

Пазарно говорене

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3.04.2025 г., 08:36 ч. UTC

Пазарно говорене

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3.04.2025 г., 07:51 ч. UTC

Пазарно говорене

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31.03.2025 г., 09:31 ч. UTC

Горещи акции

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17.03.2025 г., 14:43 ч. UTC

Пазарно говорене

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17.03.2025 г., 13:55 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17.03.2025 г., 07:04 ч. UTC

Придобивния, сливания и поглъщания

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17.03.2025 г., 07:03 ч. UTC

Придобивния, сливания и поглъщания

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17.03.2025 г., 07:03 ч. UTC

Придобивния, сливания и поглъщания

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17.03.2025 г., 07:01 ч. UTC

Придобивния, сливания и поглъщания

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17.03.2025 г., 07:01 ч. UTC

Придобивния, сливания и поглъщания

AstraZeneca Buying EsoBiotec for up to $1B

17.03.2025 г., 07:01 ч. UTC

Придобивния, сливания и поглъщания

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17.03.2025 г., 07:00 ч. UTC

Придобивния, сливания и поглъщания

AstraZeneca to Buy EsoBiotec

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26.02.2025 г., 14:59 ч. UTC

Пазарно говорене

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26.02.2025 г., 08:04 ч. UTC

Пазарно говорене
Печалби

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20.02.2025 г., 11:34 ч. UTC

Придобивния, сливания и поглъщания

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20.02.2025 г., 11:34 ч. UTC

Придобивния, сливания и поглъщания

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20.02.2025 г., 11:33 ч. UTC

Придобивния, сливания и поглъщания

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20.02.2025 г., 11:33 ч. UTC

Придобивния, сливания и поглъщания

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20.02.2025 г., 11:31 ч. UTC

Придобивния, сливания и поглъщания

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20.02.2025 г., 11:30 ч. UTC

Придобивния, сливания и поглъщания

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13.02.2025 г., 10:49 ч. UTC

Пазарно говорене
Печалби

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7.02.2025 г., 10:30 ч. UTC

Топ новини

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6.02.2025 г., 15:18 ч. UTC

Пазарно говорене

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6.02.2025 г., 13:24 ч. UTC

Пазарно говорене

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6.02.2025 г., 12:01 ч. UTC

Печалби

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6.02.2025 г., 11:22 ч. UTC

Пазарно говорене
Печалби

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

AstraZeneca PLC ADR Прогноза

Ценова цел

By TipRanks

36.11% нагоре

12-месечна прогноза

Среден 93.18 USD  36.11%

Висок 98 USD

Нисък 88 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за AstraZeneca PLC ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

N/A / 74.09Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.